Calcium Channel Blocker Market
Asia Pacific and Latin America together held approximately 28 % of total world demand in 2016 due to emerging markets in countries like India , China , and Brazil . The Asia-Pacific region is the most promising region for calcium channel blocker market and is expected to grow at the fastest CAGR in the near future . China is the biggest consumer followed by India in Asia pacific region . The demand for calcium channel blocker in Asia pacific market is anticipated to grow at a CAGR of 5.9 % in term of consumption .
Browse detail report with in-depth TOC @ https :// www . zionmarketresearch . com / report / calcium-channel-blocker-market
Increasing demand for health management is likely to open growth opportunities for the market in the near future . Calcium channel blocker is a drug mainly used in the treatment of hypertension , angina pectoris and obesity which boost the growth of the market .
The report covers detailed competitive outlook including the market share and company profiles of the key participants operating in the global calcium channel blockers which include Pfizer Inc ., AstraZeneca Plc ., Bayer Healthcare LLC ., GlaxoSmithKline Plc ., Sanofi S . A ., Johnson & Johnson , Abcam , AbMole Bioscience , and Clearsynth .